

Research Article

AI Model Developed Using Machine Learning for Predicting Sperm Retrieval in Micro-TESE for Nonobstructive Azoospermia Patients

Hideyuki Kobayashi (D, Masato Uetani, Fumito Yamabe, Yozo Mitsui, Koichi Nakajima, and Koichi Nagao

Department of Urology, Toho University School of Medicine, Tokyo, Japan

Correspondence should be addressed to Hideyuki Kobayashi; hideyukk@med.toho-u.ac.jp

Received 25 November 2022; Revised 6 June 2023; Accepted 27 October 2023; Published 8 December 2023

Academic Editor: R. Henkel

Copyright © 2023 Hideyuki Kobayashi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Azoospermia is a severe problem that prevents couples from having their own children through natural pregnancy. In nonobstructive azoospermia (NOA), microdissection testicular sperm extraction (micro-TESE) is required to collect sperm and, at 40%-60%, the sperm retrieval success rate is not very high. Previous studies identified no single clinical finding or investigation that could accurately predict the outcome of sperm retrieval. It would be very valuable to have a factor for predicting the possibility of sperm retrieval in patients with NOA before performing micro-TESE. We retrospectively obtained data from the medical records of 430 patients who underwent micro-TESE from 2011 to 2020. Parameters extracted were age, height, body weight, body mass index, luteal hormone, follicle-stimulating hormone, PRL, total testosterone, E2, T/E2, sperm retrieval, G-band, AZF, medical history, Rt testis, and Lt testis. Prediction One, which does not require coding, was used to create the AI prediction model for sperm retrieval. Prediction One makes the best prediction model using an artificial neural network with internal cross-validation. Prediction One also evaluates the "importance of variables" using a method based on permutation feature importance. The AUC for the AI model was 0.7246, which is acceptable. In addition, among the variables, T/E2 ratios contributed most to predicting whether sperm retrieval was possible or not. However, the difference in T/E2 between successful and unsuccessful sperm retrieval was not statistically significant. In addition, our analysis of data from 20 patients who underwent micro-TESE in 2021 found that in 85%, the actual result matched the result predicted using our novel AI model. We created an AI model for predicting sperm retrieval in patients with NOA before undergoing micro-TESE. In addition, we found that T/E2 ratios contributed most to predicting possibility of sperm retrieval in NOA using machine learning.

1. Introduction

Almost all couples who have normal sexual intercourse and do not use contraception achieve pregnancy within 1 year. However, a certain percentage are unable to have a child due to infertility, which affects about one in six couples. Infertility can be a problem for both women and men, affecting both genders equally [1]. Azoospermia is a severe type of male infertility that prevents couples from having their own children through natural pregnancy. Azoospermia means the inability to detect any sperm at all under a microscope when semen is centrifuged, and the process is performed at least twice [2]. Azoospermia was reportedly observed in ~16% of infertile Japanese men [3]. There are two patterns of azoospermia. The first is obstructive azoospermia (OA) and the second is nonobstructive azoospermia (NOA). In OA, spermatogenesis is normal, but sperm fails to be delivered into the ejaculate because of ductal obstruction. NOA is defined as minimal or no production of fully developed spermatozoa in the seminiferous tubules. It has been estimated that NOA accounts for 60% of azoospermia [4]. It is conventionally classified according to where it arises, as pretesticular or testicular. Pretesticular NOA is due to hypothalamic–pituitary disorders in which follicle-stimulating hormone (FSH) and luteal hormone (LH) are not produced by the pituitary, whereas testicular NOA is a disorder of spermatogenesis. There are few cases of pretesticular NOA but many of testicular NOA. In this manuscript, NOA means testicular NOA.

Testicular sperm extraction (TESE) is required for obtaining sperm from patients with azoospermia. Conventional TESE (cTESE) is performed to obtain sperm from patients with OA and NOA, while microdissection testicular sperm extraction (micro-TESE) is the gold standard for obtaining sperm from patients with NOA. Micro-TESE involves the use of optical magnification to target specific seminiferous tubules that contain mature sperms [5].

Schlegel reported that the rate of successful sperm retrieval by micro-TESE was 50%–60% in patients with NOA [5], while Amer et al. [6] reported that micro-TESE had a higher sperm retrieval rate than cTESE (47% versus 30%). Yumura et al. [3] noted a sperm retrieval rate of 34.0% when a total of 695 micro-TESEs were performed during 1 year at 24 hospitals in Japan. Thus, reported sperm retrieval rates have not been very high so far.

Abdel Raheem et al. [7] stated that there was no single clinical finding or investigation that can accurately predict the outcome of the sperm retrieval. Although clinical (patient age, smoking, testicular volume, and cryptorchidism) and hormone parameters (FSH and Inhibin B) have been previously investigated as potential predictors of sperm retrieval, the evidence for them has been conflicting and a specific biochemical marker predicting the possibility of sperm retrieval has yet to be established [8–19].

It is very valuable to know the possibility of sperm retrieval for patients with NOA before performing micro-TESE. In this regard, Zeadna et al. [20] evaluated the performance of machine-learning models in predicting successful sperm retrieval in patients with NOA but the size of the study population was a limitation on their study, as it included only 119 patients.

Artificial intelligence (AI) is used in many areas of medicine including radiology, ophthalmology, pathology, and oncology, and we previously reported the use of an AI-based algorithm for predicting Johnsen scores to evaluate spermatogenesis in the testis [21].

In this study, we attempted to make a model for predicting the possibility of sperm retrieval in patients with NOA before performing micro-TESE, using machine learning.

2. Materials and Methods

2.1. Study Population. We retrospectively obtained data from the medical records of 430 patients who underwent micro-TESE from 1 January 2011 to 31 December 2020. We also obtained data for 20 patients who underwent micro-TESE from 1 January 2021 to 31 December 2021. Azoospermia was defined as a semen sample evaluated as having no sperm according to the WHO criteria on two different occasions [2]. In addition, a centrifuged semen sample had to have no sperm under \times 400 magnification (Olympus, Inc., Tokyo, Japan). We did not use the WHO 2021 criteria because our retrospective data did not go beyond 2020. Therefore, we used the WHO 2010 criteria for this research [2]. The medical history of patients who underwent micro-TESE was recorded, which included left varicocele, cryptorchidism, inguinal hernia, torsion of spermatic cord, orchitis, cancer treatment, spinal injury, spina bifida, and antisperm antibodies.

All patients underwent a medical evaluation of secondary sexual characteristics, clinical testicular volume, and varicoceles, as well as sonography of the testis and varicoceles. Varicoceles were classified according to the Dubin and Amelar varicocele grading system [22].

We measured serum hormonal levels of FSH, LH (luteinizing hormone), PRL (prolactin), total testosterone, and E2 (estradiol). In addition, the T (testosterone)/E2 (estradiol) ratio was calculated using T in ng/dL and E2 in pg/mL. A karyotype analysis was performed in 407 patients and a Y chromosomal microdeletion analysis in 211 patients.

The Ethics Committee of Toho University Omori Medical Center has waived informed consent for this study. The study protocol was approved by the Ethics Committee of Toho University Omori Medical Center. All methods were performed in accordance with the relevant guidelines and regulations as well as with the Declaration of Helsinki. The presented study design was accepted by the Ethics Committee on the condition that a document declaring an opt-out policy, by which any potential patients and/or their relatives could refuse inclusion in this study, was uploaded to the website of the Toho University Omori Medical Center.

2.2. Surgical Technique. Micro-TESE had been performed under local anesthesia by groups of three surgeons, as described by Schlegel with some modifications [5]. The three surgeons were board certified by Japan Society for Reproductive Medicine.

A 3.0-cm transverse incision is made on the scrotal skin and, wrapped in the tunica vaginalis, the testis is delivered outside the scrotum. The tunica vaginalis is grasped with curved mosquito forceps and opened widely with curved ophthalmic scissors. At the level of the minor axis of the testis, the tunica albuginea is opened widely with a #11 blade. The bleeding from the tunica albuginea is stopped with curved mosquito forceps. The surgeon's nondominant hand holds the everted testicle while the dominant hand, with microtweezers, carefully and systematically dissects the seminiferous tubules under high-powered 15-25 optical magnification. An assistant of the surgeon irrigates the field with saline for optimal visualization. Bipolar electrocautery is used for meticulous hemostasis. Using microtweezers, the surgeon looks for prominent seminiferous tubules for collection. Regarding features, prominent seminiferous are large and tortuous and show white turbidity. After dissection is completed, the tunica albuginea is carefully closed with a running suture and interrupted suture. The tunica vaginalis is closed, the testicle is delivered back into the scrotum and the wound is closed.

Testis tissue samples were collected in four or five 1.5 mL microtubes with $200 \,\mu$ L HEPES buffer solution (P + HEPES Medium, Nakamedical, Inc., Tokyo, Japan) and were mechanically dispersed using ophthalmic scissors. The testis

Andrologia

	Sperm retrieval $(+)$	Sperm retrieval $(-)$	p Value
	55.1% (<i>n</i> =151)	64.9% (n = 279)	(<i>p</i> <0.05)
Age	39.80 ± 9.50	35.15 ± 5.69	< 0.001
Height (cm)	171.49 ± 6.13	172.03 ± 6.07	0.388
Body weight (kg)	70.36 ± 12.52	69.38 ± 9.94	0.42
Body mass index (BMI)	23.85 ± 3.63	23.45 ± 3.17	0.262
LH (mIU/mL)	8.53 ± 5.80	10.75 ± 7.08	< 0.001
FSH (mIU/mL)	18.05 ± 14.88	25.06 ± 13.90	< 0.001
PRL (ng/mL)	10.34 ± 5.99	10.52 ± 5.13	0.77
Total testosterone (ng/mL)	4.43 ± 2.56	3.96 ± 1.74	0.047
E2 (pg/mL)	25.95 ± 11.16	25.91 ± 11.38	0.973
T/E2	17.61 ± 9.06	16.63 ± 9.66	0.344
Rt testis size (mL)	12.11 ± 5.06	9.17 ± 3.78	< 0.001
Lt testis size (mL)	12.06 ± 5.03	9.01 ± 3.66	< 0.001
Johnsen score	6.58 ± 2.45	2.86 ± 1.37	< 0.001

TABLE 1: Clinical characteristics of patients with successful and unsuccessful sperm retrieval by micro-TESE.

tissue samples in the 1.5-mL microtubes were placed in a 35mm Petri dish containing HEPES buffer solution and an embryologist searched for sperm under an inverted microscope at $\times 400$ magnification in the operation room. If no sperm was found in the immediate search in the operation room, total testis tissue was spread in 5–10 Petri dishes containing HEPES buffer solution and was searched for sperm under an inverted microscope at $\times 400$ magnification by three embryologists in the embryo culture room.

2.3. Database. Age, height, body weight, body mass index (BMI), LH, FSH, PRL, total testosterone, E2, T/E2, sperm retrieval, G-band, AZF, medical history, Rt testis, and Lt testis were extracted from patient records, and Excel (Microsoft Corporation, Redmond, Washington, USA) sheets were created from the data. A total of 16 variables were extracted —consisting of numeric variables (age, height, body weight, BMI, LH, FSH, PRL, total testosterone, E2, T/E2, Rt testis, and Lt testis) and sperm retrieval, G-band, AZF, and medical history as binary variables.

2.4. Statistical Analysis. Statistical analysis was performed using IBM SPSS statistics software (Version 27) (IBM, Armonk, New York, USA). Quantitative variables are shown as averages. Quantitative variable data were investigated using the unpaired *t*-test. The homoscedasticity of data was confirmed by the Levene test. Qualitative variable data were investigated using the χ^2 -test. p < 0.05 was considered statistically significant.

2.5. Creation of Machine Learning Prediction Model Requiring No Coding Using Prediction One. Prediction One (https://predictionone.sony.biz; Sony Network Communications Inc., Tokyo, Japan) was used to make the prediction model for sperm retrieval. Prediction One is software only available in Japanese. It generates feature vectors from datasets using standard preprocessing methods, such as one-hot encoding for categorical variables and normalization for numerical variables. A gradient-boosting tree and a neural network are used as supervised machine learning models, each trained with hyperparameter tuning. An ensemble model of both trained models was constructed. Missing values are automatically handled by common machine learning techniques, such as a gradient-boosting tree. The area under the curve (AUC) was calculated using internal validation to evaluate the accuracy of the AI model. Prediction One makes the best predictive model using an artificial neural network with 5-fold cross-validation. Prediction One also evaluates the "importance of variables" using a method based on permutation feature importance. This method was used to calculate the difference in the model output when a single variable was removed. The value of the difference in the model output indicated how much the model depended on the variables. The value of the difference was computed for each covariate and then averaged over those in the dataset [23].

Prediction One read in the data of the 430 patients who underwent micro-TESE and automatically divided them into internal training and cross-validation datasets, in more or less equal halves. Prediction One automatically adjusted and optimized the variables to make it easy to process them statistically and mathematically and select an appropriate algorithm with ensemble learning. The missing values were automatically compared and Prediction One made the best prediction model using an artificial neural network with internal cross-validation. The details are trade secrets and cannot be provided.

The data from the 20 patients who underwent micro-TESE from 1 January to 31 December 2021 were used as an external validation dataset.

3. Results

The mean age of the 430 male patients who underwent micro-TESE targeted by this study was 36.78 ± 7.58 years. Sperm retrieval was successfully achieved in 151 (35.1%) patients.

Table 1 shows the clinical characteristics of patients with successful (+) and unsuccessful (-) sperm retrieval by

micro-TESE. Statistically significant differences between successful and unsuccessful sperm retrieval were observed for age, LH, FSH, total testosterone, Rt testis, Lt testis, and Johnsen score count. Patients in the successful sperm retrieval group were older (mean age 39.80 ± 9.50 years), had lower levels of LH (mean LH 8.53 ± 5.80 mIU/mL) and FSH (mean FSH 18.05 ± 14.88 mIU/mL), a higher total testosterone level (mean total testosterone 4.43 ± 2.56 ng/mL), bigger Rt testis (mean Rt testis 12.11 ± 5.06 mL), bigger Lt testis (mean Lt testis 12.06 ± 5.03 mL), and a higher Johnsen score count (mean JSC 6.58 ± 2.45).

However, no statistically significant differences were observed for height, body weight, BMI, PRL, E2, and T/E2 between unsuccessful and unsuccessful sperm retrieval.

We have provided these data for the 430 patients who underwent micro-TESE in the supplement.

Table 2 shows differences between sperm retrieval (+) and (-) for surgical site, G-band chromosome test, azoospermia factor (AZF) analysis, and medical history (none, Lt varicocele, cryptorchidism, inguinal hernia, torsion of spermatic cord, orchitis, cancer treatment, spinal injury, spina bifida, antisperm antibody (+), and others) when micro-TESE was performed. Statistically significant differences were observed in medical history between successful and unsuccessful sperm retrieval. However, differences in surgical site, G-band chromosome test, and AZF analysis between successful and unsuccessful sperm retrieval were not statistically significant.

We have provided these data for the 430 patients who underwent micro-TESE in the supplement.

Figure 1 shows the AI prediction model for sperm retrieval in micro-TESE, generated using the Prediction One software. In the accuracy evaluation of the AI prediction model, AUC was 72.46%. In addition, in a ranking of contribution of variables from 1st to 5th, "T/E2" ranked 1st.

The confusion matrix presented in Figure 2 indicates a threshold of 0.47. The values for accuracy, precision, and recall are 72.09%, 64.76% and 45.03%, respectively, when the *F*-value is 53.13%.

Table 3 presents a ranking of variables contributing to sperm retrieval (+) and (-). Rankings are shown from 1st to 10th. The variable contributing to sperm (+) and (-) ranked 1st is "T/E2 ratio." "Age" and "medical history" also rank highly for contribution to sperm (+) and (-). "FSH" ranks highly for contribution to sperm (-), while "G-band" ranks highly for contribution to sperm (+).

In 2021, we performed micro-TESE in 20 patients and investigated differences between actual results for sperm retrieval and those predicted using our AI model when the threshold was 0.47. Table 4 presents the data. Surprisingly, the actual results and predicted results were matched in 17 of the 20 patients (85.0%). In the remaining three patients, sperm could not be retrieved according to the AI model but could be retrieved in the actual micro-TESE. The patient indicated as no. 1 had cryptozoospermia or azoospermia due to rapid weight loss. We performed micro-TESE to collect sperm in all cases, even when FSH was normal.

4. Discussion

Requiring no coding, the AI approach that we adopted has the potential to accelerate access to deep learning for clinicians and clinical researchers [24]. The ability to create an AI model with no need for coding is a big advantage for doctors. We developed an AI-assisted image classifier that provides scores for histological testis images of patients with azoospermia using Google Cloud AutoML Vision. With it, testis images could be classified at 82.6% accuracy [21].

The successful sperm retrieval rate is reportedly between 40% and 60% in men with NOA [5]. Since the rate is not very high, it is important to have predictive criteria for micro-TESE outcomes in order to better counsel patients before performing micro-TESE. Previous large sample size studies were consistent in demonstrating that sperm retrieval can only be predicted with limited diagnostic accuracy even when using machine learning models [25]. To investigate this further, Zeadna et al. [20] presented a "machine learning perspective" on predicting the presence of sperm before surgery in NOA patients. Their main conclusion was that a model with FSH, LH, testosterone, semen volume, age, BMI, ethnicity, and testicular volume as predictors could predict sperm retrieval with moderate accuracy (AUC 0.8).

However, there were some problems in their study. First, the number of patients in the study population was relatively small (n = 119). Second, regarding criteria for NOA, 7.6% of the patients showed normal spermatogenesis in the testicular histology examination. Third, 25% of patients had a normal FSH level, and the mean testicular volume was 13 mL. Finally, the sperm retrieval rates were much higher (65%) than those found in the literature for TESE [26]. Therefore, it is necessary to strictly define the study population when creating a predictive model.

Although more than 20 years have passed since the first use of micro-TESE was described, an ideal model for predicting the presence or absence of sperm before micro-TESE remains elusive. In this study, our objective was to create an AI model to predict the presence or absence of sperm before micro-TESE using AI predictive modeling software with no need for coding. We successfully created the model using data from 430 patients who had undergone micro-TESE. Among the variables used, T/E2 ratio was found to be a critical factor for the presence or absence of sperm before micro-TESE.

It has been reported that the local balance between estrogen and androgen may be important for maintaining spermatogenesis [27]. In this regard, male patients with severe infertility, particularly those with NOA, have low serum T/E2 ratios. A cutoff point of 10 has been proposed as the lower limit of the ratio for adults [28]. In addition, it has been suggested that, when used together, T/E2 ratios and seminal testosterone levels may serve as good indicators for predicting the success of surgically retrieving sperm from the testes of patients with NOA [29]. Furthermore, Shiraishi et al. [30] recently reported that compared to patients with OA (n=18), in those with NOA (n=72), serum testosterone (p<0.0001) and T/E2 ratios (p<0.0001) were significantly decreased and E2 levels were significantly increased (p<0.01)

Andrologia

TABLE 2: Characteristics of patients with successful and unsuccessful sperm retrieval regarding surgical site, G-band chromosome test, azoospermia factor (AZF) analysis, and medical history.

Surgical site of micro-TESE (1) $(r_{1}, r_{2}, r_{1}, r_{2}, r_{1}, r_{2}, r_{1}, r_{2}, r_{1}, r_{2}, r_{1}, r_{2}, r_$		Sperm retrieval (+)	Sperm retrieval (–)	Total	<i>p</i> Value (<i>p</i> <0.05)
Pight 112 210 322 0.963 Left 32 56 88 Bilateral 7 13 20 Total 151 (35.1%) 279 (64.9%) 430 G-band 1 0 1 46.XY 123 230 353 0.094 46.XY/shide(IV)(q11.23)(123)(DAZ-) 1 0 1 46.XY/shide(IV)(q12,13) 0 1 1 46.XY/shide(IV)(q12,13) 0 1 1 46.XY/shide(IV)(q12,13) 0 1 1 46.XY/shide(IV)(q12,13) 1 1 2 46.XY/shide(IV)(q12,13) 1 1 2 46.XY/shide(IV)(q12,13) 1 0 1 46.XY/shide(IV)(q12,13) 1 0 1 46.XY/shide(IV)(q12,13) 1 0 1 46.XY/shide(IV)(q12,13) 1 0 1 46.XY/shide(IV)(q12,12) 1 0 1 46.XY/shide(IV)(q12,12) 0 1 1 46.XY/shide(IV)(q12,12) 0 1 1 46.XY/shide(IV)(q12,12) 0 1 1 45.XY/shide(IV)(q12,12) 0 1 1 45.XY/sh	Surgical site of micro-TESE	Sperm reuterun (1)		10100	r · (p (0.00)
Left 32 56 88 Bilateral 7 13 20 Ghand 151 (351%) 279 (64.9%) 430 G-band 123 220 353 0.094 46,XY 0 1 1 46,XY/sh5X 0 1 1 46,XY/sh5X 0 1 1 1 46,XY/sh745X 0 1 1 46,XY/sh79(p)(p12q13) 47,XXY,sh79(9)(p12q13) 0 1 1 2 46,X/sh745X 0 1 1 1 46,XY,sh79(p112q112) 1 0 1 1 46,XY,sh79(p112q112) 1 0 1 46,XY,sh745X 1 0 1 1 46,XY,sh745X 1 0 1 1 1 46,XY,sh745X 3 1 4 46,XY,sh745X 3 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	Right	112	210	322	0.963
Bilateral 7 13 20 Total 151 (35.1%) 279 (64.9%) 430 G-band	Left	32	56	88	
Total 151 (35.1%) 279 (64.9%) 430 G-band	Bilateral	7	13	20	
G-band 123 230 353 0.094 46XY 1 0 1 1 46XY, 164(1)(q11.23q11.23)(DAZ-) 1 0 1 1 46, XY, 10x(9)(p12q13) 47, XXY, 10x(9)(p12q13) 0 1 1 46, XY, 10x(9)(p12q13) 0 1 1 2 46, XY, 10x(9)(p12q13) 1 0 1 1 46, XY, 10x(10q12q12) 1 0 1 1 46, XY, 47, XY 47, XXY mosaicism 4 1 5 4 45, XY, 10x(9, 11, 20, 10x) 0 1 1 1 46, XY, 47, XYY <	Total	151 (35.1%)	279 (64.9%)	430	
46XY1232303530.094 $46XY$ '1sh del(Y)(q11.23q11.23)(DAZ-)101 $46XY$ '1sh del(Y)(q12q13) 47,XXY,inv(9)(p12q13)011 $46XY$ 'nnv(9)(p12q13) 47,XXY,inv(9)(p12q13)011 $46XY$ -mar0111 $46XY$ 'nnv(9)(p12q13)112 $46X, 'nnv(Y)(p11.2q11.2)$ 101 $46XY, 'nnv(9)(p12q13)$ 101 $47, XXY / 46, XX$ 101 $47, XXY / 45, XY$ 42428 $46, X', 'nt, 's)(r)(q35.1;q23)$ 101 $47, XXY / 47, XXY 47, XXY mosaicism41545, XY, 'dr(T, 22)(q16;q10)01146, XY, 'dr, 's)(r)(q12;q12)01146, X', (r), (r), (r), (r), (r), (r), (r), (r)$	G-band		· · · ·		
46.XY,ish del(Y)(q11.23q11.23)(DAZ-) 1 0 1 46.XY,V45,X 0 1 1 46.XY,V45,X 0 2 2 46,XY, mar 0 1 1 46,XY, fury(9)(p12q13) 1 0 1 46,XY, fury, Mar, Mar, Massian 4 1 5 45,XY, der(13,22)(q10q10) 0 1 1 46,XY (7,8)(p11,2q11,2), inv(9)(p12q13) 0 1 1 46,XY (7,8)(p11,2q11,2), inv(9)(p12q13) 0 1 1 46,XY (7,10(q12,2) 0 1 1 1 46,XY (7,10(q12,2) 0 1 1 1 46,XY (1	46,XY	123	230	353	0.094
$46\chi,Y/45\chi$ 0 1 1 $46\chi,Y$ (mv(9)(p12q1) 47,XXY,inv(9)(p12q13) 0 1 1 $46\chi,X$ 0 2 2 $46\chi,Y$ (mv(9)(p12q13) 1 1 2 $46\chi,Y$ (mv(9)(p12q13) 1 1 2 $46\chi,Y$ (mv(9)(p12q12) 1 0 1 $46\chi,Y$ (mv(9)(p12q15) 0 1 1 $45\chi,Y$ (der)(122)(p10q10) 0 1 1 $46\chi,Y$ (f,S)(p11,2q11,23),inv(9)(p12q13) 0 1 1 $46\chi,Y$ (f,S)(p11,2q11,23),inv(9)(p12q13) 0 1 1 $46\chi,Y$ (f,S)(p11,2q11,23),inv(9)(p12q13) 0 1 1 $45\chi,Y$ (der)(p1,2q1,2),inv(9)(p12q13) 0 1 1 $45\chi,Y$ (f,S)(p11,2q11,23),inv(9)(p12q13) 0 1 1 $45\chi,Y$ (f,C)(p1,2q1,2),inv(9)(p12q13) 0 1 1 $72E$ 9 2 1 1 <td>46.XY.ish del(Y)(q11.23q11.23)(DAZ-)</td> <td>1</td> <td>0</td> <td>1</td> <td></td>	46.XY.ish del(Y)(q11.23q11.23)(DAZ-)	1	0	1	
46,XY,inv(9)(p12q13) 47,XXY,inv(9)(p12q13) 0 1 1 46,XY,inv(9)(p12q13) 1 1 2 46,XY,inv(9)(p12q13) 1 1 2 46,XY,inv(9)(p12q13) 1 0 1 46,XY,inv(9)(p12q13) 1 0 1 47,XXY/46,XX 1 0 1 47,XXY 1 0 1 47,XXY,4(5)17)(q35,1;q32) 1 0 1 47,XXY,4(1;q12)(q10) 0 1 1 46,XY,47,XYY 0 1 1 72 0 1 1 72 1 1 2 <t< td=""><td>46.X.?Y/45.X</td><td>0</td><td>1</td><td>1</td><td></td></t<>	46.X.?Y/45.X	0	1	1	
46,XX, mar 0 2 2 46,XY, mar 0 1 1 46,XY, mar 0 1 1 46,XY, mar 0 1 1 46,XY, m(Y)(p11,2q11,2) 1 0 1 46,XY, Yi 0 1 1 46,XY, Yi 4 24 28 46,XY, 47,XYY 4 1 5 45,XY, 4cr (13,22) (q10,q10) 0 1 1 46,XY, (7,8) (p11,2q12) 0 1 1 46,XY, (7,8) (p11,2q12,3),inv(9) (p12q13) 0 1 1 46,XY, (7,8) (p11,2q11,23),inv(9) (p12q13) 0 1 1 7 12 9 2 2 41 63 AZFe 139 268 407 2 9 2 2 9 2 2 9 2 2 9 2 1 1 1	46,XY,inv(9)(p12q13) 47,XXY,inv(9)(p12q13)	0	1	1	
46,X,+mar 0 1 1 46,X,inv(9)(p12q13) 1 0 1 46,X,inv(Y)(p11.2q11.2) 1 0 1 46,X,Y,1q 0 1 1 47,XY 0 1 1 46,XY,ify(7)(q51:q23) 1 0 1 47,XY 4 24 28 46,XY,ider(15;22)(q10q10) 0 1 1 46,XY,ider(15;22)(q10q10) 0 1 1 46,XY,47,XYY 0 1 1 46,XY,47,89 1 1 2 72 7 1 1 1 72 9 2 1 1 72	46,XX	0	2	2	
46.X7, inv(9)(p12q13) 1 1 2 46.X7, inv(Y)(p11.2q11.2) 1 0 1 46.X7, inv(Y)(p11.2q11.2) 1 0 1 46.X7, inv(S)(7)(q12,q11.2) 1 0 1 46.X7, it(S17)(q35.1;q23) 1 0 1 47.XXY 4 24 28 46.X7/47, XXY 4 24 28 46.X7/47, XXY 7 1 1 46.X7/47, XXY 3 1 4 46.X7/47, XYY 0 1 1 46.X7/47, XYY 0 1 1 46.X1/47, XYY 0 1 1 46.X1/47, XYY 0 1 1 46.X1/47, XYY 0 1 1 46.X1/(1,2) 0 1 1 700 1 1 1 45.X1/47, XYY 0 1 1 71 13 268 407 AZE 7 2 9 AZE 7 2 9 AZE <td< td=""><td>46.X.+mar</td><td>0</td><td>1</td><td>1</td><td></td></td<>	46.X.+mar	0	1	1	
46,X;inv(Y)(p11,2q11,2) 1 0 1 $46,XY;iq$ 0 1 1 $47,XY;iq$ 0 1 1 $47,XY;iq$ 0 1 1 $47,XY;iq$ 0 1 1 $47,XY;iq$ 0 1 1 $47,XY,Yiq$ 4 24 28 $45,XY;de(i);12;q1;2)$ 0 1 1 $45,XY;de(i);22)(q10;q10)$ 0 1 1 $46,XY;fX;My,XYY$ 0 1 1 $46,XY;fX;My,My,M(y)(p12;q13)$ 0 1 1 $46,XY;f(i);M(q11,2),123)inv(9)(p12;q13)$ 0 1 1 $46,XY;f(i);M(q11,2),123)inv(9)(p12;q13)$ 0 1 1 $72F$ 0 1 1 1 $72F$ 0 1 1 1 $72F$ 9 0.063 3 2 9 $72F$ 9 0.063 3 4 1 1 $72F$ 9 0 1 1 2 9 1	46.XY.inv(9)(p12q13)	1	1	2	
46,XY,Piq 0 1 1 47,XXY 1 0 1 46,XY,f(5),7)(q35,1;q23) 1 0 1 46,XY,f(5),7)(q35,1;q23) 1 0 1 46,XY,f(7,XXY 4 24 28 46,XY,f(7,XXY 0 1 1 45,XY,4XY,4XY,4XY,4XY 0 1 1 45,XY,4XY 0 1 1 46,XY,f(7,8)(p11,2;q1,23),inv(9)(p12q13) 0 1 1 46,XY,1(7,8)(p11,2;q1,1,23),inv(9)(p12q13) 0 1 1 46,XY,1(7,8)(p11,2;q1,1,23),inv(9)(p12q13) 0 1 1 70tal 139 268 407 AZF 7 2 9 AZF 7 2 9 AZFc partial deletion (b2/b4) 7 2 9 AZFc partial deletion (b2/b3) 1 3 4 Palindrome deletion (Ym-9 P3 deletion) 1 1 2 Medical history 7 16 1 1 None 23 72 95 0	46.X.?inv(Y)(p11.2g11.2)	1	0	1	
ATXXV146,XX101 $47,XXY146,XX$ 101 $47,XXY146,XX$ 42428 $45,XY147,XXY47,XXY mosaicism41545,XY147,XXY47,XXY01145,XY147,XYY47,XXY31445,XY147,XYY47,XYY01146,XY147,XYY01146,XY147,XYY01146,XY147,XYY01145,XY,1(7,8)(p11.2,q11.23),inv(9)(p12q13)01146,XY,1(7,8)(p11.2,q11.23),inv(9)(p12q13)0117 total139268407AZF729AZF729AZF729AZF729AZF134Palindrome deletion (b2/b4)729AZF72950.011Lt varicocele143246Others5494148Cryptorchidism9514Inguinal hernia9514Corsion of spermatic cord123Orchitis314Cancer treament131629Spinal injuny336Spinal bifida314Antisperm antiboly (+)426$	46.XY.?1g	0	1	1	
46,XY,t(5;17)(q35.1;q23) 1 0 1 47,XY 4 24 28 46,XY/47,XXY 47,XXY mosaicism 4 1 5 45,XY,47(13,22)(q10q10) 0 1 1 46,XY/45,X 3 1 4 46,XY(47,XYY 0 1 1 46,XY(47,XYY 0 1 1 46,XY(7)(q12,q12) 0 1 1 46,XY(7)(q12,q12,3),inv(9)(p12q13) 0 1 1 46,XY(7)(q11,2) 0 1 1 70tal 139 268 407 AZF 7 2 9 AZFc partial deletion (b2/b4) 7 2 9 AZFc partial deletion (b2/b4) 7 2 9 AZFc partial deletion (b2/b4) 7 2 1 Palindrome deletion (Ym-9 P3 deletion) 1 1 2 Total 72 95 0.011 Medical history 7 16 1 1 Inguinal hermia 9 7 16 1	47.XXY/46.XX	1	0	1	
47,XXY 4 24 28 $45,XY/47,XXY$ $47,XXY$ 4 1 5 $45,XY/47,XXY$ $47,XXY$ 0 1 1 $45,XY/47,XYY$ 0 1 1 4 $45,XY/47,XYY$ 0 1 1 4 $45,XY/47,XYY$ 0 1 1 1 1 $45,XY/47,XYY$ 0 1 1 1 1 1 $45,XY/47,XYY$ 0 1 1 1 1<	46.XY,t(5:17)(q35.1;q23)	1	0	1	
46,XY/47,XXY 47,XXY mosaicism 4 1 5 45,XY,der(13;22)(q10;q10) 0 1 1 46,XY/45,X 3 1 4 46,XY/45,XY 0 1 1 46,XY,45,XYY 0 1 1 46,XY,47,XYY 0 1 1 46,XY,t(7;8)(p11.2;q11.2),inv(9)(p12q13) 0 1 1 46,XY,t(7;8)(p11.2;q11.2),inv(9)(p12q13) 0 1 1 Total 139 268 407 AZF 2 41 63 AZFc partial deletion (gr/gr) 22 41 63 AZFc partial deletion (b2/b3) 1 3 4 Palindrome deletion (Ym-9 P3 deletion) 1 1 2 Total 79 132 211 Medical history 7 16 1 None 23 72 95 0.011 Lt varicocele 14 32 46 0 Others 54 94 148 14 14 Torsion of spermatic cord <td< td=""><td>47.XXY</td><td>4</td><td>24</td><td>28</td><td></td></td<>	47.XXY	4	24	28	
45,XY,der(13;22)(q10;q10)01145,XY,der(13;22)(q10;q10)01146,XY,V45,X31446,XY,V47,XYY01146,X,V(17;8)(p11,2;q11,23),inv(9)(p12q13)01146,X,V(17;8)(p11,2;q11,23),inv(9)(p12q13)01146,X,V(17;8)(p11,2;q11,23),inv(9)(p12q13)0117 total139268407AZF	46.XY/47.XXY 47.XXY mosaicism	4	1	5	
46,XY/45,X314 $46,XY/45,XYY$ 011 $46,XY/47,XYY$ 011 $46,XY/47,XYY$ 011 $46,XY,t(7,8)(p11.2q,11.23),inv(9)(p12q13)$ 011 $45,X,idc(Y)(q11.2)$ 011Total139268407AZF	45.XY.der(13:22)(a10:a10)	0	1	1	
46,XY/47,XYY011 $46,XY,47,XYY$ 011 7 total139268407AZFc partial deletion (gr/gr)224163AZFc partial deletion (b2/b4)729AZFc partial deletion (b2/b4)729AZFc partial deletion (b2/b3)134Palindrome deletion (Ym-9 P3 deletion)112Total79132211Medical history134Others5494148Cryptorchidism9716Inguinal hernia9514Cryptorchidism314Cancer treament131629Spinal injury336Spina bifida314Antisperm antibody (+)426Total1625371	46.XY/45.X	3	1	4	
$46 X : (Y_1)(q_12;q_12)$ 0 1 1 $46, XY, (T_73)(p_11.2;q_11.23), inv(9)(p_12q_13)$ 0 1 1 $46, XY, (T_73)(p_11.2;q_11.23), inv(9)(p_12q_13)$ 0 1 1 Total 139 268 407 AZF No deletion 48 80 128 0.063 AZF 7 2 9 0 5 5 AZFc total deletion (b2/b4) 7 2 9 0 1 1 AZFc partial deletion (b1/b3) 0 5 5 5 1 3 4 Palindrome deletion (b2/b3) 1 1 2 2 11 1 2 1	46.XY/47.XYY	0	1	1	
$A_5,Y, (r/3)(p11,2;q11.23),inv(9)(p12q13)$ 0 1 1 $A_5,Y, (r/3)(p11,2;q11.23),inv(9)(p12q13)$ 0 1 1 Total 139 268 407 AZF No deletion 48 80 128 0.063 AZF AZF cpartial deletion (gr/gr) 22 41 63 AZF cpartial deletion (b2/b4) 7 2 9 AZF coartial deletion (b1/b3) 0 5 5 AZF coartial deletion (b2/b3) 1 3 4 Palindrome deletion (Ym-9 P3 deletion) 1 1 2 2 11 Medical history 72 95 0.011 1 1 2 3 1 4 Cryptorchidism 9 7 16 1	$46 \times t(Y:1)(a12:a12)$	0	1	1	
Total 1 1 Total 139 268 407 AZF 339 268 407 No deletion 48 80 128 0.063 AZF partial deletion (gr/gr) 22 41 63 AZF cotal deletion (b2/b4) 7 2 9 AZFc partial deletion (b1/b3) 0 5 5 AZF partial deletion (b2/b4) 7 2 9 AZFc partial deletion (b2/b4) 7 2 9 AZFc partial deletion (b2/b3) 1 3 4 Palindrome deletion (b2/b3) 1 1 2 Total 79 132 211 Medical history 1 1 2 None 23 72 95 0.011 Lt varicocele 14 32 46 Others 5 14 14 14 Cryptorchidism 9 7 16 16 Inguinal hernia 9 5 14 14 Cancer treament 13 16	46.XY, t(7:8)(p11.2;q11.23),inv(9)(p12q13)	0	1	1	
Total 139 268 407 AZF	46.X.idic(Y)(a11.2)	0	1	1	
AZF Item Item Item No deletion 48 80 128 0.063 AZF partial deletion (gr/gr) 22 41 63 AZF cotal deletion (b2/b4) 7 2 9 AZF partial deletion (b1/b3) 0 5 5 AZF partial deletion (b2/b3) 1 3 4 Palindrome deletion (Ym-9 P3 deletion) 1 1 2 Total 79 132 211 Medical history 1 2 46 None 23 72 95 0.011 Lt varicocele 14 32 46 Others 54 94 148 Cryptorchidism 9 7 16 Inguinal hernia 9 5 14 Torsion of spermatic cord 1 2 3 Orchitis 3 1 4 Cancer treament 13 16 29 Spinal injury 3 3 6 Spina bifda 3 1 4	Total	139	268	407	
No deletion48801280.063AZFc partial deletion (gr/gr) 224163AZFc total deletion $(b2/b4)$ 729AZFc partial deletion $(b1/b3)$ 055AZFc partial deletion $(b2/b3)$ 134Palindrome deletion $(Ym-9 P3 deletion)$ 112Total79132211Medical history7950.011Lt varicocele143246Others5494148Cryptorchidism9716Inguinal hernia9514Torsion of spermatic cord123Orchitis314Cancer treament131629Spinal injury336Spina bifida314Antisperm antibody (+)426Total161617	AZF	107	200	107	
AZFc partial deletion (gr/gr) 22 41 63 AZFc partial deletion (b2/b4) 7 2 9 AZFc partial deletion (b1/b3) 0 5 5 AZFc partial deletion (b2/b3) 1 3 4 Palindrome deletion (Ym-9 P3 deletion) 1 1 2 Total 79 132 211 Medical history 7 95 0.011 Lt varicocele 14 32 46 Others 54 94 148 Cryptorchidism 9 7 16 Inguinal hernia 9 5 14 Torsion of spermatic cord 1 2 3 Orchitis 3 1 4 Cancer treament 13 16 29 Spinal injury 3 3 6 Spina bifida 3 1 4 Antisperm antibody (+) 4 2 6	No deletion	48	80	128	0.063
AZFc total deletion $(b2/b4)$ 7 2 9 AZFc partial deletion $(b2/b3)$ 1 3 4 Palindrome deletion $(Ym-9 P3 deletion)$ 1 1 2 Total 79 132 211 Medical history 7 2 95 0.011 It varicocele 14 32 46 0 Others 54 94 148 0 Cryptorchidism 9 7 16 1 Inguinal hernia 9 5 14 14 2 Orchitis 3 1 4 2 3 0 Orchitis 3 1 4 <td< td=""><td>AZEC partial deletion (gr/gr)</td><td>22</td><td>41</td><td>63</td><td></td></td<>	AZEC partial deletion (gr/gr)	22	41	63	
AZFc partial deletion (b1/b3)055AZFc partial deletion (b2/b3)134Palindrome deletion (Ym-9 P3 deletion)112Total79132211Medical history2372950.011Lt varicocele143246Others5494148Cryptorchidism9716Inguinal hernia9514Torsion of spermatic cord123Orchitis314Cancer treament131629Spina hifda314Antisperm antibody (+)426	AZEc total deletion (b2/b4)	7	2	9	
AZFc partial deletion (b2/b3)134Palindrome deletion (Ym-9 P3 deletion)112Total79132211Medical history 79 13246None2372950.011Lt varicocele143246Others5494148Cryptorchidism9716Inguinal hernia9514Torsion of spermatic cord123Orchitis314Cancer treament131629Spinal injury336Spina bifida314Antisperm antibody (+)426	AZEc partial deletion $(b1/b3)$	0	5	5	
Palindrome deletion (Ym-9 P3 deletion)112Total79132211Medical history 72 950.011Lt varicocele143246Others5494148Cryptorchidism9716Inguinal hernia9514Torsion of spermatic cord123Orchitis314Cancer treament131629Spinal injury336Spina bifida314Antisperm antibody (+)426	AZEc partial deletion (b2/b3)	1	3	4	
Total 79 132 211 Medical history 23 72 95 0.011 Lt varicocele 14 32 46 Others 54 94 148 Cryptorchidism 9 7 16 Inguinal hernia 9 5 14 Torsion of spermatic cord 1 2 3 Orchitis 3 1 4 Cancer treament 13 16 29 Spinal injury 3 3 6 Spina bifida 3 1 4 Antisperm antibody (+) 4 2 6	Palindrome deletion (Ym-9 P3 deletion)	1	1	2	
Medical history2372950.011Lt varicocele143246Others5494148Cryptorchidism9716Inguinal hernia9514Torsion of spermatic cord123Orchitis314Cancer treament131629Spinal injury336Spina bifida314Antisperm antibody (+)426	Total	79	132	211	
None 23 72 95 0.011 Lt varicocele 14 32 46 Others 54 94 148 Cryptorchidism 9 7 16 Inguinal hernia 9 5 14 Torsion of spermatic cord 1 2 3 Orchitis 3 1 4 Cancer treament 13 16 29 Spinal injury 3 3 6 Spina bifida 3 1 4 Antisperm antibody (+) 4 2 6	Medical history		102	211	
Note 25 72 55 6011 Lt varicocele143246Others5494148Cryptorchidism9716Inguinal hernia9514Torsion of spermatic cord123Orchitis314Cancer treament131629Spinal injury336Spina bifida314Antisperm antibody (+)426Total136235371	None	23	72	95	0.011
Driving113216Others5494148Cryptorchidism9716Inguinal hernia9514Torsion of spermatic cord123Orchitis314Cancer treament131629Spinal injury336Spina bifida314Antisperm antibody (+)426Total136235371	Lt varicocele	14	32	46	0.011
Cryptorchidism9716Inguinal hernia9514Torsion of spermatic cord123Orchitis314Cancer treament131629Spinal injury336Spina bifida314Antisperm antibody (+)426Total136235371	Others	54	94	148	
Inguinal hernia9514Torsion of spermatic cord123Orchitis314Cancer treament131629Spinal injury336Spina bifida314Antisperm antibody (+)426Total136235371	Cryptorchidism	9	7	16	
Inguna hermaJJJTorsion of spermatic cord123Orchitis314Cancer treament131629Spinal injury336Spina bifida314Antisperm antibody (+)426Total136235371	Inguinal hernia	9	5	14	
Orchitis125Orchitis314Cancer treament131629Spinal injury336Spina bifida314Antisperm antibody (+)426Total136235371	Torsion of spermatic cord	1	2	3	
Cancer treament131629Spinal injury336Spina bifida314Antisperm antibody (+)426Total136235371	Orchitis	3	1	4	
Spinal injury336Spina bifida314Antisperm antibody (+)426Total136235371	Cancer treament	13	16	29	
Spina highSSSSpina bifda314Antisperm antibody (+)426Total136235371	Spinal injury	3	3	6	
Antisperm antibody (+) 4 2 6 Total 136 235 371	Spina hifua	3	1	4	
Total 126 225 271	Antisperm antibody (+)	4	2	т б	
	Total	136	- 235	371	

Andrologia



FIGURE 1: AI prediction model for sperm retrieval in micro-TESE based on Prediction One software.



FIGURE 2: Confusion matrix (threshold: 0.47) and values of parameters for AI model created.

[30]. They also observed that levels of aromatase, an enzyme responsible for the aromatization of androgens into estrogens, were increased in patients with NOA.

These researchers also performed univariate and multivariate analyses to predict sperm retrieval by micro-TESE in patients with NOA. Univariate analysis revealed no significant difference in T/E2 ratios between the sperm retrieval group (n = 22) and no sperm retrieval group (n = 50). In the multivariate analysis, while there was no statistically significant difference in T/E2 ratios, there was a slight difference in terms of odds ratio (odds ratio: 4.78, 95% confidence interval: 0.24–93.8) compared with LH (odds ratio: 0.91, 95% confidence interval: 0.71–1.18), FSH (odds ratio: 0.98, 95% confidence interval: 0.90–1.07), testosterone (odds ratio: 0.96, 95% confidence interval: 0.89–1.03), and estradiol (odds ratio:1.36, 95% confidence interval: 0.72–2.55) [30].

Prediction accuracy

	TABLE 3:	Ranking of va	riables contributing to sperm retrieval	(+) and (–).		
Variable strength ranking	Contribution to sperm retrieval (+)	Value	Contribution to sperm retrieval (-)	Value	Contribution to sperm retrieval (+) and (-)	Value
lst	T/E2	0.0525	T/E2	0.0565	T/E2	0.109
2nd	Age	0.0501	FSH	0.049	Age	0.0989
3rd	G-band	0.0494	Age	0.0488	Medical history	0.0962
4th	Medical history	0.049	Medical history	0.0473	FSH	0.0959
5th	BMI	0.0481	BMI	0.0466	BMI	0.0947
6th	E2	0.0476	Body weight	0.0452	Lt testis	0.0876
7th	FSH	0.0469	Lt testis	0.0408	AZF	0.0783
8th	Lt testis	0.0468	PRL	0.0401	G-band	0.075
9th	Rt testis	0.0447	AZF	0.0381	TH	0.0727
10th	AZF	0.0402	TH	0.0364	Total testosterone	0.07
Ranking is shown from 1 st to	10 th .					

-	I																			
Sperm retrieval (+) 0 (-) prediction	1	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0
Sperm retrieval 1 (+) 0 (-) real	1	0	0	1	1	0	0	0	0	0	0	0	0	0	1	0	0	1	1	0
Lt testis (mL)	15	9	12	10	10	10	4	4	10	5	8	12	8	10	9	3	3	12	12	4
Rt testis (mL)	15	9	10	10	10	10	4	4	10	5	8	12	8	10	9	3	б	12	12	5
Medical history	Others (rapid weight loss)	None	None	Others	Cryptorchidism	None	Cryptorchidism	Left VC	Others	Others	None	Cancer treatment	None	Cancer treatment	None	Others	Others	Left VC	None	None
AZF	No deletion	No deletion		AZFc(gr/gr) partial deletion	AZFc(gr/gr) partial deletion	AZFc(gr/gr) partial deletion	No deletion	AZFc(gr/gr) partial deletion	AZFc(gr/gr) partial deletion	No deletion	AZFc(gr/gr) partial deletion		No deletion	No deletion		No deletion	AZFc(gr/gr) partial deletion	AZFc(gr/gr) partial deletion	No deletion	AZFc(gr/gr) partial deletion
G-band	46,XY	46,XY	46,XY	46,XY	46,XY	46,XY	46,XY	47,XXY	46,XY	46,XY	46,XY	46,XY	46,XY	46,XY	46,XY	46,XY	47,XXY/ 46,XY	46,XY	46,XY	46,XY
T/E2	9.07	25.7	31.87	24.33	52.36	10.85	11.5	14.05	16.33	25	83.8	24.89	20.22	25.3	16.33	7.7	2.36	25.27	7.68	9.46
E2 (pg/mL)	28.1	20.7	12.3	21.7	6.8	21.1	17.3	34.3	30	16.4	5	17.6	26.7	16.8	27.8	20.4	14.4	16.5	35.8	33.6
Total testosterone (ng/mL)	2.55	5.33	3.92	5.28	5.55	2.29	1.99	4.82	4.9	4.1	4.19	4.38	5.4	4.25	4.54	1.57	0.34	4.17	2.75	3.18
PRL (ng/mL)	7.7	4.4	14.4	3.4	9.1	11.6	10.3	9.6	12.9	20.3	7.2	7.6	11.6	7.2	9	10.2	16.2	16.8	5.8	17.2
FSH (mIU/mL, IU/L	6.5	24.3	12.6	11.9	44.3	11.5	31.5	35.1	22.7	32.2	31.4	25.1	22.4	16.3	40	35.3	16.3	12	9.6	37.9
LH (mIU/mL, IU/L	3.8	8.1	4.4	8.1	18.3	4.8	20.5	18.4	8.9	14.6	6	5.9	10.7	4.5	28.2	17.6	9.4	3.6	3.8	15.4
BMI	25.7	21.2	19.27	23.53	20.76	21.89	22.76	21.73	24.16	23.81	19.72	26.06	20.05	18.37	24.91	22.06	29.76	22.99	28.06	23.15
Body weight (kg)	76	65	57	68	68	64	65	76	74	78	57	78	60	50	72	63	86	68	83	75
Height (cm)	172	175	172	170	181	171	169	187	175	181	170	173	173	165	170	169	170	172	172	180
Age	49	27	28	64	40	37	33	33	26	39	29	37	25	32	33	38	43	34	38	35
No.		2	3	4	L)	9	~	8	6	10	11	12	13	14	15	16	17	18	19	20

TABLE 4: Micro-TESE data from 20 patients in 2021 showing predicted and actual sperm retrieval results.

Although Shiraishi et al. [30] did not mention the odds ratio for T/E2 ratios, we have found that they have the potential to be a characteristic variable for predicting sperm retrieval by micro-TESE in patients with NOA and therefore included T/E2 ratios in the variables for creating the AI prediction model. Surprisingly, we found that, among the variables, T/E2 ratios contributed most to predicting possibility of sperm retrieval.

However, the reason for the lack of a statistically significant difference in T/E2 between successful and unsuccessful sperm retrieval by micro-TESE is unknown. So far, various clinical and hormone parameters have been investigated as potential predictors of successful sperm retrieval but the evidence for clinical and biochemical markers is conflicting [15]. One study found that a decreased seminal testosterone/estradiol ratio could be a good indicator for identifying absence of sperm production in NOA patients [29].

A limitation of our study is that the internal mechanism of the AI analysis system is a "black box," so it cannot be readily understood [31]. We also consider the skill of surgeons and embryologists to be a limitation for making a highly accurate AI model like the one described in our study. Prediction One found that T/E2 ratios contributed most to predicting the possibility of sperm retrieval, but we cannot ignore these limitations completely.

Based on our results, we need to further explore a value of T/E2 ratio that would help to determine whether sperm could or could not be recovered by performing micro-TESE in patients with NOA. T/E2 ratios could be a useful clinical predictor of sperm retrieval in NOA.

In our analysis of data from 20 patients who underwent micro-TESE in 2021, which were not used for training the AI model, we found that in 85% of the cases, the actual and predicted results matched. We now use the AI model to make predictions and share the information with the embryologist before micro-TESE is performed.

In conclusion, we created an AI model for predicting sperm retrieval in patients with NOA who are to undergo micro-TESE. The AUC of our AI model was 0.7246, which is acceptable. In addition, we found that, among the variables, T/E2 ratios contributed most to predicting possibility of sperm retrieval. T/E2 ratios have the potential to be a clinical predictor of sperm retrieval in NOA.

Data Availability

H.K. has ownership for the data used with Prediction One. The data collected during this study are patient data obtained with the Ethics Committee's approval and can be shared in other research. All data generated or analyzed during this study are included in this published article.

Disclosure

A preprint has previously been published [32].

Conflicts of Interest

All authors have no competing interests to declare.

Authors' Contributions

All authors contributed to the conception and design of the study. H.K. collected the data to build an AI model from clinical records, provided training in the automated machine learning models, and drafted the manuscript.

Acknowledgments

H.K. has received support in the form of a grant-in-aid for Scientific Research (C) from the Japan Society for the Promotion of Science (JSPS) (JSPS KAKENHI grant number JP22K09486).

References

- [1] A. Agarwal, A. Mulgund, A. Hamada, and M. R. Chyatte, "A unique view on male infertility around the globe," *Reproductive Biology and Endocrinology*, vol. 13, Article ID 37, 2015.
- [2] T. G. Cooper, E. Noonan, S. von Eckardstein et al., "World Health Organization reference values for human semen characteristics," *Human Reproduction Update*, vol. 16, no. 3, pp. 231–245, 2010.
- [3] Y. Yumura, A. Tsujimura, T. Imamoto et al., "Nationwide survey of urological specialists regarding male infertility: results from a 2015 questionnaire in Japan," *Reproductive Medicine and Biology*, vol. 17, no. 1, pp. 44–51, 2018.
- [4] G. Robin, F. Boitrelle, X. Leroy et al., "Assessment of azoospermia and histological evaluation of spermatogenesis," *Annales De Pathologie*, vol. 30, no. 3, pp. 182–195, 2010.
- [5] P. N. Schlegel, "Testicular sperm extraction: microdissection improves sperm yield with minimal tissue excision," *Human Reproduction*, vol. 14, no. 1, pp. 131–135, 1999.
- [6] M. Amer, A. Ateyah, W. Zohdy, T. Abd El Nasser, G. Abdel-Malak, and E. Fakhry, "Preoperative and intraoperative factors that predict difficult testicular sperm retrieval in patients with nonobstructive azoospermia," *Fertility and Sterility*, vol. 78, no. 3, pp. 646-647, 2002.
- [7] A. Abdel Raheem, G. Garaffa, N. Rushwan et al., "Testicular histopathology as a predictor of a positive sperm retrieval in men with non-obstructive azoospermia," *BJU International*, vol. 111, no. 3, pp. 492–499, 2013.
- [8] P. Salehi, M. Derakhshan-Horeh, Z. Nadeali et al., "Factors influencing sperm retrieval following testicular sperm extraction in nonobstructive azoospermia patients," *Clinical* and Experimental Reproductive Medicine, vol. 44, no. 1, pp. 22–27, 2017.
- [9] G. Corona, S. Minhas, A. Giwercman et al., "Sperm recovery and ICSI outcomes in men with non-obstructive azoospermia: a systematic review and meta-analysis," *Human Reproduction Update*, vol. 25, no. 6, pp. 733–757, 2019.
- [10] B. N. Jahromi, S. Zeyghami, M. E. Parsanezhad et al., "Determining an optimal cut-off value for follicle-stimulating hormone to predict microsurgical testicular sperm extraction outcome in patients with non-obstructive azoospermia," *Archives of Endocrinology and Metabolism*, vol. 64, no. 2, pp. 165–170, 2020.
- [11] R. Ramasamy, K. Lin, L. V. Gosden, Z. Rosenwaks, G. D. Palermo, and P. N. Schlegel, "High serum FSH levels in men with nonobstructive azoospermia does not affect success of microdissection testicular sperm extraction," *Fertility and Sterility*, vol. 92, no. 2, pp. 590–593, 2009.

- [12] Q. Yang, Y.-P. Huang, H.-X. Wang et al., "Follicle-stimulating hormone as a predictor for sperm retrieval rate in patients with nonobstructive azoospermia: a systematic review and meta-analysis," *Asian Journal of Andrology*, vol. 17, no. 2, pp. 281–284, 2015.
- [13] F. Boitrelle, G. Robin, F. Marcelli et al., "A predictive score for testicular sperm extraction quality and surgical ICSI outcome in non-obstructive azoospermia: a retrospective study," *Human Reproduction*, vol. 26, no. 12, pp. 3215–3221, 2011.
- [14] Y. Nagata, K. Fujita, J. Banzai et al., "Seminal plasma inhibin-B level is a useful predictor of the success of conventional testicular sperm extraction in patients with non-obstructive azoospermia," *Journal of Obstetrics and Gynaecology Research*, vol. 31, no. 5, pp. 384–388, 2005.
- [15] T. Tharakan, R. Luo, C. N. Jayasena, and S. Minhas, "Nonobstructive azoospermia: current and future perspectives," *Faculty Reviews*, vol. 10, Article ID 7, 2021.
- [16] K. A. Toulis, P. K. Iliadou, C. A. Venetis et al., "Inhibin B and anti-Mullerian hormone as markers of persistent spermatogenesis in men with non-obstructive azoospermia: a metaanalysis of diagnostic accuracy studies," *Human Reproduction Update*, vol. 16, no. 6, pp. 713–724, 2010.
- [17] V. Vernaeve, H. Tournaye, J. Schiettecatte, G. Verheyen, A. Van Steirteghem, and P. Devroey, "Serum inhibin B cannot predict testicular sperm retrieval in patients with non-obstructive azoospermia," *Human Reproduction*, vol. 17, no. 4, pp. 971– 976, 2002.
- [18] S. von Eckardstein, M. Simoni, M. Bergmann et al., "Serum inhibin B in combination with serum follicle-stimulating hormone (FSH) is a more sensitive marker than serum FSH alone for impaired spermatogenesis in men, but cannot predict the presence of sperm in testicular tissue samples," *The Journal of Clinical Endocrinology & Metabolism*, vol. 84, no. 7, pp. 2496– 2501, 1999.
- [19] Z.-G. Zhu, Z.-G. Zhao, Q.-Y. Pang et al., "Predictive significance of serum inhibin B on testicular haploid gamete retrieval outcomes in nonobstructive azoospermic men," *Asian Journal of Andrology*, vol. 21, no. 2, pp. 137–142, 2019.
- [20] A. Zeadna, N. Khateeb, L. Rokach et al., "Prediction of sperm extraction in non-obstructive azoospermia patients: a machinelearning perspective," *Human Reproduction*, vol. 35, no. 7, pp. 1505–1514, 2020.
- [21] Y. Ito, M. Unagami, F. Yamabe et al., "A method for utilizing automated machine learning for histopathological classification of testis based on Johnsen scores," *Scientific Reports*, vol. 11, Article ID 9962, 2021.
- [22] L. Dubin and R. D. Amelar, "Varicocele size and results of varicocelectomy in selected subfertile men with varicocele," *Fertility and Sterility*, vol. 21, no. 8, pp. 606–609, 1970.
- [23] J. Mazaki, K. Katsumata, Y. Ohno et al., "A novel predictive model for anastomotic leakage in colorectal cancer using autoartificial intelligence," *Anticancer Research*, vol. 41, no. 11, pp. 5821–5825, 2021.
- [24] E. Korot, Z. Guan, D. Ferraz et al., "Code-free deep learning for multi-modality medical image classification," *Nature Machine Intelligence*, vol. 3, pp. 288–298, 2021.
- [25] R. Ramasamy, W. O. Padilla, E. C. Osterberg et al., "A comparison of models for predicting sperm retrieval before microdissection testicular sperm extraction in men with nonobstructive azoospermia," *Journal of Urology*, vol. 189, no. 2, pp. 638–642, 2013.
- [26] G. Verheyen, B. Popovic-Todorovic, and H. Tournaye, "Processing and selection of surgically-retrieved sperm for ICSI: a review," *Basic and Clinical Andrology*, vol. 27, Article ID 6, 2017.

- [27] L. O'Donnell, K. M. Robertson, M. E. Jones, and E. R. Simpson, "Estrogen and spermatogenesis," *Endocrine Reviews*, vol. 22, no. 3, pp. 289–318, 2001.
- [28] C. P. Pavlovich, P. King, M. Goldstein, and P. N. Schlegel, "Evidence of a treatable endocrinopathy in infertile men," *Journal of Urology*, vol. 165, no. 3, pp. 837–841, 2001.
- [29] Q. Zhang, Q. Bai, Y. Yuan, P. Liu, and J. Qiao, "Assessment of seminal estradiol and testosterone levels as predictors of human spermatogenesis," *Journal of Andrology*, vol. 31, no. 2, pp. 215–220, 2010.
- [30] K. Shiraishi, S. Oka, and H. Matsuyama, "Testicular testosterone and estradiol concentrations and aromatase expression in men with nonobstructive azoospermia," *The Journal of Clinical Endocrinology & Metabolism*, vol. 106, no. 4, pp. 1803–1815, 2021.
- [31] Y. LeCun, Y. Bengio, and G. Hinton, "Deep learning," *Nature*, vol. 521, pp. 436–444, 2015.
- [32] H. Kobayashi, M. Uetani, F. Yamabe, Y. Mitsui, K. Nakajima, and K. Nagao, "AI model developed using machine learning for predicting sperm retrieval in micro TESE for non-obstructive azoospermia patients," *PREPRINT (Version 1) available at Research Square*, 2022.